Get started
Author

N. Varol

Observed names: N Varol, Nebibe Varol, Varol, Nebibe
ORCID: 0000-0003-4157-5962
Observed ORCID: 0000-0003-4157-5962
OpenAlex ID: A5029910628
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis
2019 · Frank Griesinger, Ellen E. Korol, et al. · Lung Cancer · 162
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States
2015 · Volker Foos, Nebibe Varol, et al. · Journal of Medical Economics · 122
PDF
Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries
2014 · Victoria Divino, Mitch DeKoven, et al. · Diabetes Therapy · 41
PDF
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis
2023 · Kenneth O'Byrne, Evan Popoff, et al. · Lung Cancer · 33
PDF
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey
2023 · Hollie Bailey, Adam Lee, et al. · BMC Cancer · 28
PDF
Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies
2022 · Adam Lee, Yong Yuan, et al. · Cancer Treatment and Research Communications · 16
PDF
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
2022 · Sarah Goring, Nebibe Varol, et al. · Lung Cancer · 15
MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
2021 · M. Berling, M.A. Chaudhary, et al. · Journal of Thoracic Oncology · 10
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
2018 · Chris Kiff, Sandrine Ruiz, et al. · International Journal of COPD · 10
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
2022 · Maria Polyzoi, Hera Sandhu, et al. · Journal of Medical Economics · 8
PDF
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer
2024 · Martin Reck, Tuli De, et al. · Clinical Lung Cancer · 7
PDF
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
2022 · Malin Berling, Mohammad A. Chaudhary, et al. · Journal of Medical Economics · 7
Predicting the Frequency of Severe and Non-Severe Hypoglycaemia in Insulin Treated Type-2 Diabetes Subjects
2013 · P. McEwan, V. Foos, et al. · Value in Health · 4
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis
2024 · Nicolas Girard, Mariam Besada, et al. · Cancers · 3
1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
2022 · M. Reck, T. De, et al. · Annals of Oncology · 2
Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes
2014 · N. Hawkins, A. Padhiar, et al. · Value in Health · 2
EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis
2023 · K. O'Byrne, E. Popoff, et al. · Journal of Thoracic Oncology · 1
PDF
P15 Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched "Time Zero": Methodology and Application in Resectable Non-Small Cell Lung Cancer
2023 · S. Goring, B. Rogula, et al. · Value in Health · 1
PDF
107P The evolving diagnostic and treatment landscape in metastatic non-small cell lung cancer (mNSCLC) across Europe: A real world evidence survey
2021 · H. Bailey, A. Lee, et al. · Annals of Oncology · 1
PDF
EC1 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
2021 · M. Polyzoi, H. Sandhu, et al. · Value in Health · 1
PCN91 Estimating EQ-5D Utilities for Cost-Effectiveness Models Involving Immuno-Oncology Treatments
2020 · M.A. Chaudhary, X. Sun, et al. · Value in Health · 1
Pcn39 Treatment Effect Modification of Immunotherapy-based Regimens in First-line (1l) Advanced Non-small Cell Lung Cancer (ansclc): a Systematic Review of Randomized Controlled Trials (rcts)
2020 · S.M. Goring, N. Waser, et al. · Value in Health · 1
Pcn56 - Treatment Effect Modification (em) of Anticancer Therapies in First-line Advanced Non-small Cell Lung Cancer (ansclc): a Systematic Assessment of Trial Data
2018 · S. Wang, N. Varol, et al. · Value in Health · 1
PDF
GLP1 and Insulin Glargine Treatment Patterns Among Type 2 Diabetes Patients in Major EU Markets
2013 · V. Divino, S. Hallinan, et al. · Value in Health · 1
Quantifying the Direct and Indirect Costs Associated with Severe and Non-Severe Hypoglycaemia in Subjects with Type-2 Diabetes Who Are Treated with Insulin
2013 · V. Foos, D. Grant, et al. · Value in Health · 1
Works count: 46
Citation count: 480
H-index: 9
I10-index: 9
Year
Topic
Type